Stereotaxis, Inc. (STXS) is a Healthcare stock trading at $1.45 (as of 2026-08-20), with a market capitalization of $141.23M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Stereotaxis, Inc. develops and sells robotic magnetic navigation systems, related imaging hardware, and procedure information solutions used in interventional labs. Its offerings include RMN systems for image-guided catheter and guidewire navigation, real-time networking software to manage and share procedures, and associated disposables and accessories.
Stereotaxis designs, manufactures, and markets robotic magnetic navigation systems and related instruments and information systems for interventional labs, making money by selling its Systems and by generating ongoing Revenue from Disposables, Service and Accessories tied to those procedures.
The companys profit model is built around an installed-base dynamic, where initial Systems sales can be complemented by ongoing recurring Revenue from Disposables, Service and Accessories (captured in its Recurring Revenue metric).
| Systems | $0.0B |
| DSA | $0.0B |
Business quality (Weak): Readable business model and operating KPI are provided, but the latest quarter shows 0.0B revenue across both reported segments, so results and segment trends may reflect timing rather than underlying demand.
| Price | $1.45 |
| Market Cap | $141.23M |
| Price / Book | 9.84 |
| Price / Sales | 4.53 |
| FCF Yield | -8.1% |
| Revenue (TTM) | $32.38M |
| Net Margin | -66.8% |
| Revenue Growth (YoY) | -15.8% |
| EPS Growth (YoY) | -14.3% |
| Altman Z-Score | -13.97 (distress) |
| Sector P/E (Healthcare) | 21.6 |
| Industry P/E (Medical Equipment) | 32.9 |
| Top Institutional Holder | DAFNA Capital Management LLC ($25.17M) |
| Institutional Holders Tracked | 10 |
| Sector | Healthcare |
| Industry | Medical Equipment |
| CEO | David Leo Fischel |
| Employees | 139 |
| Country | US |
| IPO Date | 2004-08-12 |
Data as of 2026-08-20.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.